Evotec SE : Legal and operating risks after CEO’s resignation appear limited – slump in share price exaggerated – buying opportunity
>Legal risks at a corporate level should be low… - There was a conference call held this afternoon (22 Jan 2024), which clearly indicated that Evotec's former CEO, Werner Lanthaler, deliberately violated compliance rules, when he did not disclose several director’s dealings. Among other transactions, Werner Lanthaler did not report material disposals of Evotec shares immediately before the publication of quarterly figures (after which the share price fell sharply). Th...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.